Market Overview

UPDATE: Credit Suisse Downgrades Johnson & Johnson to Underperform on Valuation

Related JNJ
The 4 Companies Teaming Up For A New Tool To Fight Cancer
#PreMarket Primer: Friday, August 22: Draghi, Yellen Set To Speak At Jackson Hole
Johnson & Johnson CEO: No Plans to Leave U.S. (Fox Business)

Credit Suisse downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Underperform and raised the price target from $71.00 to $73.00.

Credit Suisse commented, "Concurrent with Credit Suisse rating methodology requiring that ratings now reflect an expectation of relative out/(under) performance versus an analyst's coverage universe, we downgrade JNJ to Underperform from Neutral. While we advocate overweight positions in pharma stocks and acknowledge the stock's "index importance", JNJ offers the lowest total return in our coverage universe (dividend plus equity), hence this change. Along with adjustments to target price to other stocks in our sector, we raise JNJ's target to $73 from $71, below its current level of $75."

Johnson & Johnson closed at $75.39 on Wednesday.

Posted-In: Credit SuisseAnalyst Color Downgrades Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters